Your browser doesn't support javascript.
Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B.
Liu, Jun; Budylowski, Patrick; Samson, Reuben; Griffin, Bryan D; Babuadze, Giorgi; Rathod, Bhavisha; Colwill, Karen; Abioye, Jumai A; Schwartz, Jordan A; Law, Ryan; Yip, Lily; Ahn, Sang Kyun; Chau, Serena; Naghibosadat, Maedeh; Arita, Yuko; Hu, Queenie; Yue, Feng Yun; Banerjee, Arinjay; Hardy, W Rod; Mossman, Karen; Mubareka, Samira; Kozak, Robert A; Pollanen, Michael S; Martin Orozco, Natalia; Gingras, Anne-Claude; Marcusson, Eric G; Ostrowski, Mario A.
  • Liu J; Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Budylowski P; Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Samson R; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
  • Griffin BD; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
  • Babuadze G; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada.
  • Rathod B; Sunnybrook Research Institute, Toronto, ON, Canada.
  • Colwill K; Sunnybrook Research Institute, Toronto, ON, Canada.
  • Abioye JA; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada.
  • Schwartz JA; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada.
  • Law R; Providence Therapeutics Holdings Inc., Calgary, AB, Canada.
  • Yip L; Providence Therapeutics Holdings Inc., Calgary, AB, Canada.
  • Ahn SK; Department of Immunology, University of Toronto, Toronto, ON, Canada.
  • Chau S; Sunnybrook Research Institute, Toronto, ON, Canada.
  • Naghibosadat M; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
  • Arita Y; Department of Immunology, University of Toronto, Toronto, ON, Canada.
  • Hu Q; Sunnybrook Research Institute, Toronto, ON, Canada.
  • Yue FY; Providence Therapeutics Holdings Inc., Calgary, AB, Canada.
  • Banerjee A; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada.
  • Hardy WR; Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Mossman K; Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK, Canada.
  • Mubareka S; Department of Veterinary Microbiology, University of Saskatchewan, Saskatoon, SK, Canada.
  • Kozak RA; Department of Biology, University of Waterloo, Waterloo, ON, Canada.
  • Pollanen MS; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada.
  • Martin Orozco N; Department of Medicine, McMaster University, Hamilton, ON, Canada.
  • Gingras AC; Sunnybrook Research Institute, Toronto, ON, Canada.
  • Marcusson EG; Department of Laboratory Medicine and Pathology, University of Toronto, Toronto, ON, Canada.
  • Ostrowski MA; Sunnybrook Research Institute, Toronto, ON, Canada.
Sci Adv ; 8(3): eabj9815, 2022 Jan 21.
Article in English | MEDLINE | ID: covidwho-1634773
ABSTRACT
Safe and effective vaccines are needed to end the COVID-19 pandemic. Here, we report the preclinical development of a lipid nanoparticle­formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three candidates after the initial mouse vaccination results showed that it elicited the strongest neutralizing antibody response against SARS-CoV-2. Further tests in mice and hamsters indicated that PTX-COVID19-B induced robust humoral and cellular immune responses and completely protected the vaccinated animals from SARS-CoV-2 infection in the lung. Studies in hamsters also showed that PTX-COVID19-B protected the upper respiratory tract from SARS-CoV-2 infection. Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern, including the Alpha, Beta, Gamma, and Delta lineages. No adverse effects were induced by PTX-COVID19-B in either mice or hamsters. Based on these results, PTX-COVID19-B was authorized by Health Canada to enter clinical trials in December 2020 with a phase 2 clinical trial ongoing.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / MRNA Vaccines Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Traditional medicine / Vaccines / Variants Limits: Animals / Female / Humans / Male Country/Region as subject: North America Language: English Journal: Sci Adv Year: 2022 Document Type: Article Affiliation country: Sciadv.abj9815

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / MRNA Vaccines Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Traditional medicine / Vaccines / Variants Limits: Animals / Female / Humans / Male Country/Region as subject: North America Language: English Journal: Sci Adv Year: 2022 Document Type: Article Affiliation country: Sciadv.abj9815